AST-1306
AST-1306 Basic information
- Product Name:
- AST-1306
- Synonyms:
-
- AST-1306
- ALS 1306
- N-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin-6-yl]acrylamide
- N-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propenamide
- Allitinib (AST1306)
- Allitinib
- CS-590
- N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)quinazolin-6-yl)acrylamide
- CAS:
- 897383-62-9
- MF:
- C24H18ClFN4O2
- MW:
- 448.88
- Mol File:
- 897383-62-9.mol
AST-1306 Chemical Properties
- Boiling point:
- 655℃
- Density
- 1.395
- Flash point:
- 350℃
- storage temp.
- Store at -20°C
- solubility
- ≥22.45 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
- form
- solid
- pka
- 12.16±0.43(Predicted)
- color
- White to off-white
- InChIKey
- MVZGYPSXNDCANY-UHFFFAOYSA-N
- SMILES
- C(NC1C=CC2C(C=1)=C(NC1=CC=C(OCC3=CC=CC(F)=C3)C(Cl)=C1)N=CN=2)(=O)C=C
AST-1306 Usage And Synthesis
Uses
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB4 with IC50 of 0.5 nM and 0.8 nM, respectively.
Uses
AST-1306 is a selective irreversible inhibitor of the epidermal growth factor receptor (EGFR) 1 and 2. Studies show that AST-1306 inhibited the enzymatic activities of wild-type EGF) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. AST-1306 was more effective in inhibiting tumors with ErbB2-overexpressing cells than EGFR-overexpressing tumor.
Definition
ChEBI: N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide is a member of quinazolines.
Biological Activity
ast1306 is a novel inhibitor of egfr and her2 (ic50 = 0.5 nm and 3 nm respectively)egfr (epidermal growth factor receptor) is a cell-surface receptor tyrosine kinase. the receptor activation leads to dimerization and tyrosine autophosphorylation. it induces a cascade of downstream cellular responses such as modification in gene expression, cell proliferation and cytoskeletal rearrangement etc. her2 is a member of the epidermal growth factor and is associated with breast and ovarian cancers.ast1306 selectively blocked egfr and her2 kinase activities in a cell-free assay. the tyrosine kinase activity of egfr mutant t790m/l858r was also inhibited by ast1306 in intact cell and cell-free assays. in addition, ast1306 attenuated the egfr and her2 phosphorylation and downstream substrates. [1]in erbb2-overexpressing xenograft and fvb-2/nneu transgenic mouse model, ast1306 potently inhibited tumor growth. in sk-ov-3 xenograft model, ast1306 caused a quick and long-lasting (≥24h) inhibition of egfr and her2. [1]
in vivo
AST1306 (AST-1306; p.o.; 25-100 mg/kg; twice daily; for 28 days) causes a dramatic suppression of tumor growth in SK-OV-3 and Calu-3 xenograft models[1].
| Animal Model: | Nude mice with SK-OV-3 and Calu-3 tumors[1] |
| Dosage: | 25, 50, 100 mg/kg |
| Administration: | p.o; twice daily; for 28 days |
| Result: | Caused a dramatic suppression of tumor growth. |
IC 50
EGFR: 0.5 nM (IC50); EGFRL858R/T790M: 12 nM (IC50); ErbB2: 3 nM (IC50); ErbB4: 0.8 nM (IC50)
References
1. xie h, lin l, tong l et al. ast1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. plos one. 2011;6(7):e21487.
AST-1306Supplier
- Tel
- 0550-5196001 15000891977
- wj520wjxby@126.com
- Tel
- sales@boylechem.com
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 0531-88811783
- sales@trio-pharmatech.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com